Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Part of paid clinical trials in Tampa, Florida.

Sponsor
Revolution Medicines, Inc.
Study ID
NCT07805954
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • daraxonrasib — DRUG
    oral tablets
  • gemcitabine — DRUG
    intravenous (IV) infusion
  • nab-paclitaxel — DRUG
    IV infusion
  • zoldonrasib — DRUG
    oral tablets

Study Details

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

Key Dates

First listed
Sep 8, 2026
Start date
Aug 28, 2026
Status verified
Aug 2026
Primary completion
Mar 31, 2029
Completion
Apr 30, 2030

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: daraxonrasib + zoldonrasib
    combination of study drugs
  • Experimental: Arm B: gemcitabine and nab-paclitaxel
    chemotherapy

Primary Outcome Measure

Progression free survival (PFS) [ Time Frame: Up to approximately 4 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Moffitt Cancer CenterTampaFlorida33612
Cheyenne Schneider
[email protected]
813-745-5166

Find similar trials in Tampa, FL

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials
By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Moffitt Cancer Center· Tampa, FL

Related Studies